SuperNova1987A
Moderator
Source: Hemispherx Biopharma, Inc. http://www.globenewswire.com/newsroom/news.html?d=166653
Japanese National Institute of Infectious Diseases Scientists Identify Hemispherx Biopharma's Drug Technology as the "Most Promising Mucosal Adjuvant for Influenza"
Topical Application Also Affords Strong Cross-Protection Against Variant Flu Strains
PHILADELPHIA, June 4, 2009 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE Amex:HEB) announced today that a new peer reviewed publication titled "Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses" was published in Therapeutics and Clinical Risk Management 2009:5 125-132. The article summarizes ongoing research in which researchers conclude that Poly I
olyC12U (Ampligen(r)), an experimental therapeutic, is the "most promising adjuvant candidate for mucosal vaccines." Poly IolyC12U (Ampligen(r)), an experimental therapeutic, was also "extremely important" in these studies, in that it produced cross-protection against variant influenza viruses not seen with the vaccines given alone.
Mucosal immunity has many potential advantages (please see Nature Medicine, supplement article titled "Mucosal Immunity and Vaccines" Vol. 11, number 4, pp. S45-S53). These advantages include a better stimulation of natural immunity than conventionally applied vaccines (intramuscular injection). Since most infections affect or start from a mucosal surface, topical application is often required to induce a protective immune response. However, in practice, it is often difficult to stimulate a strong SIgA immune response by mucosal administration of antigens given alone. Injectable vaccines can also give severe local reactions and the magnitude/ duration of protection may be less by parenteral (needle) delivery than by the topical application described by the JIID researchers.
The conclusion of the JIID researchers is that a pandemic of new influenza virus seems possible, and because it will be difficult to know when a pandemic will occur (or which strain of virus will be the cause), it is in the global community's best interest to develop broadly effective and safe vaccines against influenza virus. Hence, in the need for development of a broadly effective vaccine, induction of mucosal immunity is an inevitable requirement, as mucosal secretory IgA plays an important role in cross protection. Vaccines designed to induce mucosal immunity are necessary, in the JIID view, to combat a new influenza pandemic.
Today, Hemispherx Biopharma is summarizing its new influenza prevention/treatment data at a special Symposium on Pandemic Influenza in Rome under auspices of the Italian Government, which will include an update on the Japanese collaborations.
-snip-
***********************************
I wonder if it is OK to post a company's announcement like this?
_______________________________________
SN1987A
Japanese National Institute of Infectious Diseases Scientists Identify Hemispherx Biopharma's Drug Technology as the "Most Promising Mucosal Adjuvant for Influenza"
Topical Application Also Affords Strong Cross-Protection Against Variant Flu Strains
PHILADELPHIA, June 4, 2009 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE Amex:HEB) announced today that a new peer reviewed publication titled "Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses" was published in Therapeutics and Clinical Risk Management 2009:5 125-132. The article summarizes ongoing research in which researchers conclude that Poly I
olyC12U (Ampligen(r)), an experimental therapeutic, is the "most promising adjuvant candidate for mucosal vaccines." Poly IolyC12U (Ampligen(r)), an experimental therapeutic, was also "extremely important" in these studies, in that it produced cross-protection against variant influenza viruses not seen with the vaccines given alone. Mucosal immunity has many potential advantages (please see Nature Medicine, supplement article titled "Mucosal Immunity and Vaccines" Vol. 11, number 4, pp. S45-S53). These advantages include a better stimulation of natural immunity than conventionally applied vaccines (intramuscular injection). Since most infections affect or start from a mucosal surface, topical application is often required to induce a protective immune response. However, in practice, it is often difficult to stimulate a strong SIgA immune response by mucosal administration of antigens given alone. Injectable vaccines can also give severe local reactions and the magnitude/ duration of protection may be less by parenteral (needle) delivery than by the topical application described by the JIID researchers.
The conclusion of the JIID researchers is that a pandemic of new influenza virus seems possible, and because it will be difficult to know when a pandemic will occur (or which strain of virus will be the cause), it is in the global community's best interest to develop broadly effective and safe vaccines against influenza virus. Hence, in the need for development of a broadly effective vaccine, induction of mucosal immunity is an inevitable requirement, as mucosal secretory IgA plays an important role in cross protection. Vaccines designed to induce mucosal immunity are necessary, in the JIID view, to combat a new influenza pandemic.
Today, Hemispherx Biopharma is summarizing its new influenza prevention/treatment data at a special Symposium on Pandemic Influenza in Rome under auspices of the Italian Government, which will include an update on the Japanese collaborations.
-snip-
***********************************
I wonder if it is OK to post a company's announcement like this?
_______________________________________
SN1987A